ERBB3 and neoplasm: Here, we report the results of SOLTI-1805 TOT-HER3 part B trial and the results of the exploratory study, including genomic analyses on baseline tumor samples from the SOLTI-1805 TOT-HER3 trial, with the aim of better understanding the biological features associated with early response from HER3-DXd monotherapy.